Market closedNon-fractional

Taysha Gene Therapies/TSHA

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Taysha Gene Therapies

Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.

Ticker

TSHA

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Dallas, United States

Employees

52

TSHA Metrics

BasicAdvanced
$433M
Market cap
-
P/E ratio
-$0.75
EPS
0.39
Beta
-
Dividend rate
$433M
0.39
3.38
3.209
109.586
109.586
-21.67%
-38.86%
-606.69%
24.015
7.48
7.48
-4.459
96.39%
-71.91%
-40.71%

What the Analysts think about TSHA

Analyst Ratings

Majority rating from 10 analysts.
Buy

TSHA Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-705.88% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$3.4M
-5.56%
Net income
-$24M
-150.31%
Profit margin
-705.88%
-153.27%

TSHA Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 8.59%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.38
-$0.93
$0.92
-$0.10
-
Expected
-$0.31
-$0.17
-$0.11
-$0.11
-$0.17
Surprise
22.14%
438.51%
-936.36%
-8.59%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Taysha Gene Therapies stock?

Taysha Gene Therapies (TSHA) has a market cap of $433M as of July 06, 2024.

What is the P/E ratio for Taysha Gene Therapies stock?

The price to earnings (P/E) ratio for Taysha Gene Therapies (TSHA) stock is 0 as of July 06, 2024.

Does Taysha Gene Therapies stock pay dividends?

No, Taysha Gene Therapies (TSHA) stock does not pay dividends to its shareholders as of July 06, 2024.

When is the next Taysha Gene Therapies dividend payment date?

Taysha Gene Therapies (TSHA) stock does not pay dividends to its shareholders.

What is the beta indicator for Taysha Gene Therapies?

Taysha Gene Therapies (TSHA) has a beta rating of 0.39. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy or sell Taysha Gene Therapies stock

Buy or sell Taysha Gene Therapies stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing